Exact Sciences Reports Strong Q4 & Full-Year 2025 Results Amidst Pending Acquisition

summarizeSummary

Exact Sciences announced robust fourth quarter and full-year 2025 financial results, including significant revenue growth and improved cash flow, as the company approaches a shareholder vote on its acquisition by Abbott Laboratories.

check_boxKey Events

• Strong Q4 2025 Revenue Growth

  Total revenue increased 23% to $878 million in Q4 2025, driven by strong performance in both Screening and Precision Oncology segments.

• Significant Full-Year 2025 Financial Improvement

  Full-year revenue reached $3.25 billion (up 18%), with operating cash flow increasing 133% to $491 million and free cash flow surging 379% to $357 million.

• Reduced Net Loss

  The full-year 2025 net loss significantly improved to $208 million compared to $1.028 billion in 2024.

• Context of Pending Merger

  These results precede a shareholder vote on February 20, 2026, for the proposed acquisition by Abbott Laboratories at $105.00 per share, with the company's stock currently trading near this price.

auto_awesomeAnalysis

Exact Sciences reported strong financial performance for Q4 and full-year 2025, highlighted by a 23% increase in Q4 revenue to $878 million and an 18% full-year revenue increase to $3.25 billion. The company also demonstrated substantial improvements in profitability and cash generation, with full-year operating cash flow up 133% to $491 million and free cash flow surging 379% to $357 million. While the company still reported a net loss, the full-year loss significantly narrowed compared to the prior year. These positive results reinforce the company's operational strength and come just days before a critical shareholder meeting on February 20, 2026, to vote on the proposed acquisition by Abbott Laboratories for $105.00 per share. The stock is currently trading near this acquisition price, suggesting the market largely anticipates the deal's completion.